You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapse refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jan 5, 2023

Advanced Pancreatic Cancer Trial in Nanjing (Adoptive TIL-TCM transfer therapy)

Recruiting
  • Advanced Pancreatic Cancer
  • Adoptive TIL-TCM transfer therapy
  • Nanjing, Jiangsu, China
    Jinling Hospital
Jun 29, 2022

Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytosis
  • L-DEP and PD-1 antibody
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 19, 2022

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)

Recruiting
  • CD19+ Relapse/Refractory B-ALL
  • CAR-T-19 Cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 26, 2022

Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)

Recruiting
  • Refractory/Relapse Acute Myeloid Leukemia
  • Kunming, Yunnan, China
    Department of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023

Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors With Lung Metastases Trial in Fukuoka (Biological)

Recruiting
  • Refractory/Relapse Neuroblastoma
  • Pediatric Solid Tumors With Lung Metastases
  • Biological
  • Fukuoka, Japan
    Kyushu University Hospital
Nov 7, 2022

B-Cell Lymphoma, MDS (MDS), Acute Myeloid Leukemia (AML) Trial in Houston (Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells,

Not yet recruiting
  • B-Cell Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 12, 2022

MMRR Treated With Belantamab Mafotidine on Monotherapy

Not yet recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • (no location specified)
May 23, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Lymphoma, B-Cell Trial in Belgium, France (Valemetostat tosylate)

Recruiting
  • Lymphoma, B-Cell
  • Valemetostat tosylate
  • Bruges, Belgium
  • +21 more
Jan 9, 2023

Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Diffuse Scleroderma Trial in Shanghai (BRL-301)

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • +5 more
  • BRL-301
  • Shanghai, Shanghai, China
    Shanghai ChangZheng hospital
May 7, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Oct 30, 2023

    Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

    Recruiting
    • Acute Myeloid Leukemia Refractory
    • Acute Myeloid Leukemia, in Relapse
    • anti Tim-3/CD123 CAR-T cell therapy
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 4, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • (no location specified)
    Nov 9, 2023

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Diffuse Large B-cell Lymphoma Trial in Beijing (TQ-B3525 tablets)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • TQ-B3525 tablets
    • Beijing, Beijing, China
    • +1 more
    Aug 17, 2021

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia With Failed Remission
    • São Paulo, SP, Brazil
      Instituto do Cancer do Estado de Sao Paulo
    Sep 12, 2023

    Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

    Not yet recruiting
    • Refractory Multiple Myeloma
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Nov 17, 2023

    Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • Changchun, China
    • +5 more
    Jan 27, 2023

    Learn How Triple Class Refractory Multiple Myeloma Are Treated

    Not yet recruiting
    • Relapse Multiple Myeloma
    • Refractory Multiple Myeloma
      • (no location specified)
      Feb 15, 2023

      T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

      Withdrawn
      • T-cell Acute Lymphoblastic Leukemia
      • T-lymphoblastic Lymphoma
      • Target CD7 CAR-T cells
      • Kunming, Yunnan, China
        920th Hospital of Joint Logistics Support Force of People's Libe
      Nov 23, 2022

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Jun 8, 2023

      Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

      Not yet recruiting
      • Multiple Myeloma
      • Multiple Myeloma in Relapse
      • Belantamab mafodotin, Venetoclax
      • (no location specified)
      May 10, 2023